Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML

Abstract: The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/ref...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Julia M. Unglaub, Richard F. Schlenk, Jan Moritz Middeke, Stefan W. Krause, Sabrina Kraus, Hermann Einsele, Michael Kramer, Sven Zukunft, Joseph Kauer, Simon Renders, Elena Katelari, Christoph Schliemann, Caroline Pabst, Thomas Luft, Peter Dreger, Christoph Röllig, Martin Bornhäuser, Carsten Müller-Tidow, Tim Sauer
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2025-01-01
Schriftenreihe:	Blood Advances
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2473952924005585
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!